Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in Stable Sickle Cell Disease
NCT05904093Phase 1Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fostamatinib in sickle cell disease (SCD) (2 cohorts), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Safety and tolerability of fostamatinib at Day 70. Started Dec 2024; status: recruiting.
02
Drugs
fostamatinib
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05904093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904093.